Evidence map›Paper›PMID 36829653›Full record

ArticleBioengineering (Basel, Switzerland)2023

De Novo Design of Imidazopyridine-Tethered Pyrazolines That Target Phosphorylation of STAT3 in Human Breast Cancer Cells.

Akshay Ravish, Rashmi Shivakumar, Zhang Xi, Min Hee Yang, Ji-Rui Yang, Ananda Swamynayaka, Omantheswara Nagaraja, Mahendra Madegowda, Arunachalam Chinnathambi, Sulaiman Ali Alharbi and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioengineering (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.5field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. STAT3 signaling inhibitors for cancer treatment.Trends in pharmacological sciences · 2026
    Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 5 countries.

Akshay RavishLaboratory of Chemical Biology, Department of Studies in Organic Chemistry, University of Mysore, Manasagangotri, Mysore 570006, India.ORCID 0000-0001-6068-9290
Rashmi ShivakumarLaboratory of Chemical Biology, Department of Studies in Organic Chemistry, University of Mysore, Manasagangotri, Mysore 570006, India.
Zhang XiShenzhen Bay Laboratory, Shenzhen 518055, China.ORCID 0000-0003-4093-0897
Min Hee YangDepartment of Science in Korean Medicine, Kyung Hee University, Seoul 02447, Republic of Korea.
Ji-Rui YangTsinghua Berkeley Shenzhen Institute, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China.ORCID 0000-0003-2224-7648
Ananda SwamynayakaDepartment of Studies in Physics, University of Mysore, Manasagangotri, Mysore 570006, India.ORCID 0000-0003-3146-5188
Omantheswara NagarajaDepartment of Studies in Physics, University of Mysore, Manasagangotri, Mysore 570006, India.
Mahendra MadegowdaDepartment of Studies in Physics, University of Mysore, Manasagangotri, Mysore 570006, India.ORCID 0000-0002-8543-1947
Arunachalam ChinnathambiDepartment of Botany and Microbiology, College of Science, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia.ORCID 0000-0001-5075-5901
Sulaiman Ali AlharbiDepartment of Botany and Microbiology, College of Science, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia.
Vijay PandeyTsinghua Berkeley Shenzhen Institute, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China.ORCID 0000-0001-8704-0694
Gautam SethiDepartment of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117600, Singapore.
Kwang Seok AhnDepartment of Science in Korean Medicine, Kyung Hee University, Seoul 02447, Republic of Korea.ORCID 0000-0002-2882-0612
Peter E LobieShenzhen Bay Laboratory, Shenzhen 518055, China.
Basappa BasappaLaboratory of Chemical Biology, Department of Studies in Organic Chemistry, University of Mysore, Manasagangotri, Mysore 570006, India.ORCID 0000-0002-8844-468X
University of Mysore · INKing Saud University · SAKyung Hee University · KRShenzhen Bay Laboratory · CNTsinghua–Berkeley Shenzhen Institute · CNNational University of Singapore · SG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In breast cancer (BC), STAT3 is hyperactivated. This study explored the design of imidazopyridine-tethered pyrazolines as a de novo drug strategy for inhibiting STAT3 phosphorylation in human BC cells. This involved the synthesis and characterization of two series of compounds namely, 1-(3-(2,6-dimethylimidazo [1,2-a]pyridin-3-yl)-5-(3-nitrophenyl)-4,5-dihydro-1H-pyrazol-1-yl)-2-(4-(substituted)piperazin-1-yl)ethanone and N-substituted-3-(2,6-dimethylimidazo[1,2-a]pyridin-3-yl)-5-(3-nitrophenyl)-4,5-dihydro-1H-pyrazoline-1-carbothioamides. Compound

Indexed as

de novo designDFThuman breast cancerimidazopyridinepyrazolinesSTAT3

Identifiers

PMID36829653
PMCPMC9952374
OpenAlexW4317932587

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.